In addition, in the setting of surgically resectable NSCLC, EGFR mutation analysis is the only clinically required genetic test, because osimertinib, an EGFR inhibitor, is the only approved molecular targeted drug in the adjuvant setting in many countries including Japan for surgically resected pathological-stage (pStage) IB-III NSCLC patients with activating EGFR mutations [6]. Here, EGFR is linked to non-small cell lung carcinoma.